









Märkte
/
Aktien
/
nasdaq-bhvn
/

Biohaven Ltd

BHVN

17.390USD

-0.720-3.98%

Handelsschluss 10/30, 16:00（ET）Kurse um 15 Minuten verzögert

1.84BMarktkapitalisierung

VerlustKGV TTM



Biohaven Ltd

17.390

-0.720-3.98%

Übersicht Unternehmen Finanzen Analyse

Übersicht

Unternehmen

Finanzen

Analyse

mehr Informationen über Biohaven Ltd Unternehmen

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.

Biohaven Ltd Informationen



BörsenkürzelBHVN

Name des UnternehmensBiohaven Ltd

IPO-datumSep 23, 2022

CEODr. Vlad Coric, M.D.

Anzahl der mitarbeiter256

WertpapierartOrdinary Share

GeschäftsjahresendeSep 23

Addresse215 Church Street

StadtNEW HAVEN

BörseNYSE Consolidated

LandUnited States of America

Postleitzahl06510

Telefon12034040410

Websitehttps://www.biohaven.com/

BörsenkürzelBHVN

IPO-datumSep 23, 2022

CEODr. Vlad Coric, M.D.

Führungskräfte von Biohaven Ltd



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

1.62M

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Kishan (Kishen) Mehta

Director

22.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Mr. Robert J. Hugin

Independent Director

12.96K

Dr. Irina Antonijevic, M.D., Ph.D.

Independent Director

Mr. John W. Childs

Independent Director

Dr. Vlad Coric, M.D.

Chairman of the Board, Chief Executive Officer

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

1.62M

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Kishan (Kishen) Mehta

Director

22.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sat, Aug 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

1919 Investment Counsel, LLC

6.23%

Childs John W

6.15%

BlackRock Institutional Trust Company, N.A.

6.08%

Suvretta Capital Management, LLC

5.31%

Janus Henderson Investors

4.78%

Andere

71.44%

Aktionäre

Anteil

1919 Investment Counsel, LLC

6.23%

Childs John W

6.15%

BlackRock Institutional Trust Company, N.A.

6.08%

Suvretta Capital Management, LLC

5.31%

Janus Henderson Investors

4.78%

Andere

71.44%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

28.64%

Investment Advisor/Hedge Fund

25.57%

Hedge Fund

16.33%

Individual Investor

11.13%

Research Firm

3.53%

Venture Capital

1.11%

Sovereign Wealth Fund

0.85%

Corporation

0.48%

Pension Fund

0.46%

Andere

11.89%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

557

87.60M

82.81%

-13.24M

2025Q2

561

102.09M

99.98%

-11.50M

2025Q1

573

104.91M

102.74%

-8.33M

2024Q4

560

105.43M

103.87%

-2.30M

2024Q3

544

99.41M

101.90%

-4.10M

2024Q2

514

95.57M

103.25%

+3.60M

2024Q1

494

86.58M

104.39%

-3.45M

2023Q4

444

83.44M

104.38%

+4.72M

2023Q3

398

73.50M

107.61%

-2.29M

2023Q2

372

72.49M

106.13%

-7.40M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

1919 Investment Counsel, LLC

6.60M

6.23%

+2.50K

+0.04%

Jun 30, 2025

Childs John W

6.51M

6.15%

+351.58K

+5.71%

Mar 10, 2025

BlackRock Institutional Trust Company, N.A.

6.44M

6.08%

+113.23K

+1.79%

Jun 30, 2025

Suvretta Capital Management, LLC

5.62M

5.31%

Jun 30, 2025

Janus Henderson Investors

5.05M

4.78%

-1.38M

-21.51%

Jun 30, 2025

State Street Investment Management (US)

3.54M

3.34%

+115.81K

+3.38%

Jun 30, 2025

Coric (Vladimir)

3.18M

+26.57K

+0.84%

Mar 10, 2025

T. Rowe Price Associates, Inc.

3.08M

2.91%

+340.20K

+12.40%

Jun 30, 2025

The Vanguard Group, Inc.

9.23M

8.72%

+828.80K

+9.87%

Jun 30, 2025

Bellevue Asset Management AG

2.80M

2.65%

+762.00K

+37.34%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Mon, Oct 6

Name

Anteil

iShares Neuroscience and Healthcare ETF

2.95%

Roundhill GLP-1 & Weight Loss ETF

1.88%

Simplify Health Care ETF

1.12%

Virtus LifeSci Biotech Clinical Trials ETF

0.77%

SPDR S&P Biotech ETF

0.45%

WisdomTree BioRevolution Fund

0.31%

Direxion Daily S&P Biotech Bull 3X Shares

0.27%

Inspire Small/Mid Cap ESG ETF

0.2%

JPMorgan Fundamental Data Science Small Core ETF

0.18%

iShares Biotechnology ETF

0.13%

iShares Neuroscience and Healthcare ETF

Anteil2.95%

Roundhill GLP-1 & Weight Loss ETF

Anteil1.88%

Simplify Health Care ETF

Anteil1.12%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil0.77%

SPDR S&P Biotech ETF

Anteil0.45%

WisdomTree BioRevolution Fund

Anteil0.31%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.27%

Inspire Small/Mid Cap ESG ETF

Anteil0.2%

JPMorgan Fundamental Data Science Small Core ETF

Anteil0.18%

iShares Biotechnology ETF

Anteil0.13%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

KeyAI

